Navigation Links
Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
Date:2/12/2008

QUAKERTOWN, Pa., Feb. 12 /PRNewswire-FirstCall/ -- Cellegy Pharmaceuticals, Inc. (OTC Bulletin Board: CLGY) today announced that it has entered into a definitive merger agreement providing for the acquisition of Cellegy by Adamis Pharmaceuticals Corporation. Adamis is a privately held specialty pharmaceuticals company that is engaged in the research, development and commercialization of products for the prevention of viral infections, including influenza. Adamis currently markets and sells a line of prescription products for a variety of allergy, respiratory disease and pediatric conditions, and also owns a GMP certified independent contract packager of pharmaceutical and nutraceutical products. Adamis' chief executive officer, Dr. Dennis Carlo, is expected to become the chief executive officer of the combined company. Dr. Carlo is a veteran of the pharmaceutical and biotechnology industry, having previously served as CEO of publicly traded Immune Response Corporation, president of Telos Pharmaceuticals, and Vice President of Research and Development and Therapeutic manufacturing of Hybritech Inc. prior to its acquisition by Eli Lilly & Co.

The transaction was unanimously approved by the boards of directors of both companies and is anticipated to close during the second or third quarter of 2008, subject to the filing of a registration statement and proxy statement with the Securities and Exchange Commission, the approval of Adamis' and Cellegy's respective stockholders at stockholder meetings following distribution of a definitive proxy statement, and other customary closing conditions. Holders of approximately 40% of Cellegy's outstanding common stock have entered into voting agreements pursuant to which they agreed to vote their shares in favor of the transaction. The combined company expects to continue to be publicly traded after completion of the merger, although under a different corporate name.

"The merger of Cellegy and Adamis will creat
'/>"/>

SOURCE Cellegy Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
2. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
3. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
4. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
5. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
6. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
7. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
8. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. SGX Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Immune Pharmaceuticals Inc., or "Immune" (NASDAQ: ... elected Rene-Pierre Azria as a Director and ... oversight on strategic and financial transactions. Mr. Azria will ... Compensation Committee and the Corporate Governance and Nomination Committee. ... have a long-time interest in Life Sciences and in ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading ... of Josh Forsythe as VP of Marketing. Mr. ... witnessed a significant expansion in its commercial operations over the ... " Josh Forsythe is a tremendous addition ... MD MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing ...
(Date:4/21/2015)... Limited (ASX:NRT; NASDAQ: NVGN ) ("Company" or "Novogen"), ... entered into definitive agreements today to issue approximately ... 6-month option and half of one attaching 5-year ... investors in the United States ... proceeds of approximately AU$15,500,000 ("Placement"). The closing of ...
(Date:4/21/2015)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) announced ... financial results before market open on Tuesday, April 28, ... teleconference on Tuesday, April 28, 2015, at 9:00 a.m. ... with international callers dialing 1-970-315-0533.  A rebroadcast of the ...
Breaking Biology Technology:Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 2Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 3Immune Board Elects Rene-Pierre Azria A Director And Chair Of The Transaction Committee 4Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 2Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 3Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 4Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 5Novogen Conducts Private Placement and Announces Rights Offering to Shareholders 6
... , , MENLO ... California-based partners hosted the California Bioscience Business Roundtable (BBR) event at ... featured Sam Youngman, the White Correspondent for The Hill newspaper, who ... debate in Washington, D.C. , , Bioscience represents ...
... , , The statement below is from Pete ... Company, its employees and its Board of Directors. , , ... across a remarkably broad spectrum of issues. Foremost among them was his ... , , He was a tireless advocate for patients, rights ...
... 11%, - Strong Research and Investment Effort, - Positive net Financial Position, - Annual ... Saporta approved the 2009 half year financial statements: , , In million Euros ... ... Sales 87.0 ...
Cached Biology Technology:California Life Science, Business, and Economic Development Experts Discuss California's Bioscience Future 2Boston Scientific Statement on the Passing of Senator Edward Kennedy 2STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 2STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 3STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations 4
(Date:3/31/2015)... --  Guidepoint , a leading global research services firm, ... TRACKER, part of the Guidepoint TRACKER suite ... device and therapeutics markets. The Post-Surgical Pain Management TRACKER ... share, and adoption rates across three major modalities used ... The Post-Surgical Pain Management TRACKER will provide length ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Bethesda, MD This FASEB Science Research Conference brings ... define how the conformations of cellular proteins are achieved ... aberrant protein conformations arise. Specific sessions ... pathways, the mechanisms of action of molecular chaperones, pathways ...
... JUPITER, FL, January 22, 2013 How aging affects ... that makes it more difficult to treat a range ... A new study from the Florida campus of The ... affects the brain,s neural circuitry, in some cases significantly ...
... accurate information about endangered bats, birds and insects. A new ... revealed many previously unknown and highly valuable details about bats. ... in tents for several days with binoculars and infrared cameras ... system, which for two months has continuously recorded bat activity ...
Cached Biology News:Scripps Florida scientists offer new insight into neuron changes brought about by aging 2New monitoring technique reveals endangered animals 2New monitoring technique reveals endangered animals 3
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
... MSY2/YBOX2 ( Abpromise for all ... Synthetic peptide derived from a ... human YBX2. (Note: the exact ... Entrez Gene ...
Rabbit polyclonal to YANK2 ( Abpromise for all tested applications). Antigen: A KLH conjugated synthetic peptide selected within aa 300~400 (C terminal region) of human YANK2. Entrez Gene ID:...
Certified by the Biological Stain Commission. For staining fresh peripheral blood smears and blood parasites....
Biology Products: